CL2023002843A1 - Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente - Google Patents
Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamenteInfo
- Publication number
- CL2023002843A1 CL2023002843A1 CL2023002843A CL2023002843A CL2023002843A1 CL 2023002843 A1 CL2023002843 A1 CL 2023002843A1 CL 2023002843 A CL2023002843 A CL 2023002843A CL 2023002843 A CL2023002843 A CL 2023002843A CL 2023002843 A1 CL2023002843 A1 CL 2023002843A1
- Authority
- CL
- Chile
- Prior art keywords
- antigen
- binding fragment
- specifically binds
- monoclonal antibody
- methods
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- FFILOTSTFMXQJC-QCFYAKGBSA-N (2r,4r,5s,6s)-2-[3-[(2s,3s,4r,6s)-6-[(2s,3r,4r,5s,6r)-5-[(2s,3r,4r,5r,6r)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(e)-3-hydroxy-2-(octadecanoylamino)octadec-4-enoxy]oxan-3-yl]oxy-3-hy Chemical compound O[C@@H]1[C@@H](O)[C@H](OCC(NC(=O)CCCCCCCCCCCCCCCCC)C(O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@@H]([C@@H](N)[C@H](O)C2)C(O)C(O)CO[C@]2(O[C@@H]([C@@H](N)[C@H](O)C2)C(O)C(O)CO)C(O)=O)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 FFILOTSTFMXQJC-QCFYAKGBSA-N 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 3
- 230000001404 mediated effect Effects 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2021107773A RU2796937C2 (ru) | 2021-03-24 | Моноклональное антитело или его антигенсвязывающий фрагмент, которое специфически связывается с gd2 (ганглиозид gd2), и его применение |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023002843A1 true CL2023002843A1 (es) | 2024-03-22 |
Family
ID=83395963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023002843A CL2023002843A1 (es) | 2021-03-24 | 2023-09-25 | Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente |
Country Status (9)
| Country | Link |
|---|---|
| CN (1) | CN117677695A (zh) |
| AR (1) | AR125219A1 (zh) |
| CL (1) | CL2023002843A1 (zh) |
| CO (1) | CO2023012549A2 (zh) |
| CR (1) | CR20230456A (zh) |
| EC (1) | ECSP23072412A (zh) |
| TW (1) | TW202304989A (zh) |
| UY (1) | UY39687A (zh) |
| WO (1) | WO2022203552A1 (zh) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005070967A2 (en) * | 2004-01-22 | 2005-08-04 | Merck Patent Gmbh | Anti-cancer antibodies with reduced complement fixation |
| US9315585B2 (en) * | 2010-06-19 | 2016-04-19 | Memorial Sloan Kettering Cancer Center | Anti-GD2 antibodies |
| KR102207859B1 (ko) * | 2013-03-15 | 2021-01-27 | 메모리얼 슬로안 케터링 캔서 센터 | 고 친화도 항-gd2 항체 |
-
2022
- 2022-03-24 TW TW111111114A patent/TW202304989A/zh unknown
- 2022-03-24 UY UY0001039687A patent/UY39687A/es unknown
- 2022-03-24 CN CN202280024459.8A patent/CN117677695A/zh active Pending
- 2022-03-24 WO PCT/RU2022/050096 patent/WO2022203552A1/en active Application Filing
- 2022-03-24 CR CR20230456A patent/CR20230456A/es unknown
- 2022-03-25 AR ARP220100720A patent/AR125219A1/es unknown
-
2023
- 2023-09-22 EC ECSENADI202372412A patent/ECSP23072412A/es unknown
- 2023-09-22 CO CONC2023/0012549A patent/CO2023012549A2/es unknown
- 2023-09-25 CL CL2023002843A patent/CL2023002843A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP23072412A (es) | 2023-10-31 |
| CR20230456A (es) | 2023-12-13 |
| CN117677695A (zh) | 2024-03-08 |
| TW202304989A (zh) | 2023-02-01 |
| UY39687A (es) | 2022-08-31 |
| AR125219A1 (es) | 2023-06-28 |
| WO2022203552A1 (en) | 2022-09-29 |
| CO2023012549A2 (es) | 2023-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019008010A2 (pt) | anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica | |
| PE20211284A1 (es) | Anticuerpos anti-nkg2a y usos de los mismos | |
| PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
| CL2023002690A1 (es) | Anticuerpos anti-muc16-cd3 biespecíficos y conjugados anti-muc16-fármacos (divisional de 202102645) | |
| MX2020003888A (es) | Anticuerpos terapeuticos postraduccionalmente modificados completamente humanos. | |
| PE20190440A1 (es) | Anticuerpos a la alfa-sinucleina y usos de los mismos | |
| PE20210342A1 (es) | Anticuerpos anti-sirpa y metodos de utilizacion de los mismos | |
| PE20191079A1 (es) | Inmunoglobulinas y usos de estas | |
| BR112015018203A2 (pt) | Anti-corpos biespecíficos anti-tnf-anti-il-17 | |
| PE20180249A1 (es) | Anticuerpos neutralizadores anti-ccl20 | |
| WO2021227307A8 (zh) | 抗cd73抗体及其用途 | |
| BR112017027702A2 (pt) | anticorpos antirreceptor do fator de crescimento endotelial vascular 2 (vegfr2) | |
| EA202192907A1 (ru) | Моноклональное антитело, которое специфически связывается с gitr | |
| EA201890805A1 (ru) | Биспецифические антитела против cd3*cd19 | |
| Maleki et al. | Large scale generation and characterization of anti-human CD34 monoclonal antibody in ascetic fluid of Balb/c mice | |
| EA202092125A1 (ru) | Антитела против рецептора фолата 1 и их применения | |
| PE20230464A1 (es) | Union de anticuerpos multiespecificos a bcma | |
| BR112022000628A2 (pt) | Anticorpos anti-tigit e aplicação dos mesmos | |
| PE20211792A1 (es) | Anticuerpos monoclonales que se unen especificamene a la region beta de la familia trbv-9 del receptor de celulas t humano, y los metodos para su uso | |
| RU2017145662A (ru) | Моноклональные антитела и способы их применения | |
| CL2023002843A1 (es) | Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente | |
| AR127635A1 (es) | ANTICUERPO MONOCLONAL O FRAGMENTO DE UNIÓN A UN ANTÍGENO QUE SE UNE ESPECÍFICAMENTE A LA IL-4Ra, Y USO DEL MISMO | |
| BR112018070452A2 (pt) | um inibidor do receptor de hutnfr1, uma preparação farmacêutica compreendendo o referido inibidor, um método de produção do referido inibidor, uso do referido inibidor na fabricação de um produto para tratamento de um indivíduo humano, um ácido nucleico isolado que codifica o referido inibidor, vetor de expressão e células hospedeiras compreendendo o referido ácido nucleico | |
| ECSP23097121A (es) | Anticuerpo biespecífico aislado que se une específicamente a CD47 y PD-L1 | |
| BR112022020716A2 (pt) | Anticorpos anti-tumor associados ao antígeno e usos dos mesmos |